Watson Next Target As Purdue Protects Insomnia Drug Patent

Law360, New York (August 30, 2012, 1:28 PM EDT) -- Purdue Pharmaceutical Products LP on Monday expanded its efforts to protect its insomnia treatment Intermezzo, leveling a new patent infringement suit against Watson Pharmaceuticals Inc. in New Jersey federal court.

In allegations closely resembling those lodged against generic-drug maker Actavis Inc. last week, Purdue says Watson is seeking regulatory permission to manufacture its own Intermezzo clone, in violation of Purdue’s patent rights. The patent-in-suit is U.S. Patent Number 7,682,628, titled “compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof,” issued to...
To view the full article, register now.